Even if the company undertakes a Phase 2 human trial program, it won't amount to much more than the multi-dose trial in any case - maybe marginally more participants.
If a Phase 2 program is undertaken it is almost certainly on the advice of our consultants with an eye to anticipating the inconsistencies of the US FDA.
oxymorphone patch m eets phase 1 end points, page-3
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.923M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 35 | 43609108 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 44263580 | 22 |
View Market Depth
| Last trade - 10.38am 03/10/2024 (20 minute delay) ? |
| AVE (ASX) Chart |
Day chart unavailable